Tisotumab vedotin - Genmab/Seattle Genetics

Drug Profile

Tisotumab vedotin - Genmab/Seattle Genetics

Alternative Names: Humax TF ADC; HuMax-TF; HuMax-TF-ADC; TF-011-MMAE; Tisotumab vedotin

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genmab
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Cervical cancer; Endometrial cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 10 Oct 2017 Genmab plans the phase II registrational GCT1015-04 study for Cervical cancer (Metastatic disease, Second-line or greater therapy, Monotherapy) in the first half of 2018
  • 08 Sep 2017 Phase-II clinical trials in Bladder cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom, Sweden, Denmark, Belgium, USA (Parenteral) before September 2017
  • 08 Sep 2017 Phase-II clinical trials in Cervical cancer (Second-line therapy or greater, Recurrent, Metastatic disease) in Belgium, Sweden, USA, United Kingdom, Denmark (Parenteral) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top